BPC-157 Peptide: Dosage, Benefits, Side Effects & Protocol

What is BPC-157?#

BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protein found in gastric juice. It was originally isolated by researchers studying the cytoprotective properties of gastric peptides and has been studied primarily for its effects on tissue repair, wound healing, and gut integrity. BPC-157 has never been approved by the FDA for human use and is not a prescription medication. It is classified as a research chemical and is sold for laboratory use. Despite this regulatory status, it has become one of the most widely used peptides in the self-experimentation community due to its apparently broad tissue repair properties and favourable safety profile in animal studies. The compound is stable in human gastric juice, which is why it is studied in both oral and subcutaneous forms. Animal studies have investigated effects on tendon and ligament healing, muscle repair, nerve regeneration, gut inflammation, and bone healing.

BPC-157 benefits: what the evidence shows#

The majority of BPC-157 research is in animal models (rats and mice), with no completed large randomised controlled trials in humans. This is an important caveat — animal-to-human translation is not guaranteed. Tendon and ligament healing: Multiple rat studies show accelerated Achilles tendon repair, superior collagen organisation, and faster return to function compared to controls. The proposed mechanism involves upregulation of growth hormone receptor expression in tendon fibroblasts and promotion of angiogenesis (new blood vessel formation). This is probably the best-supported application of BPC-157 in the animal literature. Muscle repair: Studies show faster healing of muscle crush injuries and transection injuries, with improved force generation in treated animals. Effects appear to involve promotion of satellite cell activity and reduced inflammatory damage. Gut and GI tract: BPC-157 was originally studied for its GI effects. Animal studies show protective effects against NSAID-induced gut damage, healing of inflammatory bowel lesions, and improved integrity of the intestinal barrier. Oral administration is effective for GI targets. Nerve regeneration: Rat studies show improved recovery from peripheral nerve crush injuries and transection injuries. This is a more preliminary area with less replication. Systemic effects: BPC-157 has been proposed to have systemic anti-inflammatory effects via modulation of the NO-system and interactions with dopamine and serotonin pathways. The evidence for systemic effects in humans is entirely anecdotal.

All known efficacy data for BPC-157 is from animal studies. Human clinical trial data does not yet exist.

BPC-157 dosage guide#

There is no established human dose for BPC-157, as no clinical trials have been conducted. The doses used in the self-experimentation community are extrapolated from animal study doses scaled to human body weight. Typical dosage range: 200–500 mcg per injection Common protocol: 250–500 mcg once or twice daily For acute injury: twice daily (morning and evening) to maintain more consistent plasma levels given the ~4-hour half-life For general recovery/maintenance: once daily Cycle length: 4–12 weeks depending on injury severity Injection location: For musculoskeletal injuries, injection near (but not directly into) the injured tissue is theorised to be more effective than distant sites. For GI applications, oral administration is commonly used, as BPC-157 is stable in gastric juice. Subcutaneous vs intramuscular: Subcutaneous is most common for general use. Some protocols use intramuscular injection near the target tissue for joint or muscle injuries. Oral: BPC-157 in oral capsule form is used specifically for gut-related applications (IBD, leaky gut). The bioavailability via oral route for systemic effects is uncertain.

BPC-157 side effects#

BPC-157 has a notably clean safety profile in animal studies — no dose-limiting toxicity has been identified even at doses far exceeding typical use doses. This is part of why it's become popular in the self-experimentation community. Reported side effects in human use (self-reported, not from clinical trials): - Mild nausea, particularly with higher doses - Dizziness or light-headedness, especially shortly after injection - Injection site reactions (redness, minor swelling) - Vivid dreams reported by some users - Transient fatigue or "die-off" feeling in the first few days (proposed to be inflammatory response) Notably absent from reports: significant hormonal disruption, organ toxicity, or carcinogenicity signals in animal studies. Unlike peptides that modulate the GH axis (CJC-1295, GHRP-6), BPC-157 does not appear to raise IGF-1 levels. Unknown risks: Long-term effects in humans are unknown due to the absence of clinical trials. The safety profile in animal studies is reassuring but not a guarantee of equivalent human safety.

How to reconstitute BPC-157#

BPC-157 comes as a lyophilised (freeze-dried) powder in a sealed vial, typically 5mg. Before injecting, you dissolve the powder with bacteriostatic water (BAC water). Step 1: Gather your supplies. You need: BPC-157 vial, bacteriostatic water, insulin syringes (U-100), alcohol swabs. Step 2: Determine your target concentration. A common approach for a 5mg vial: - Add 2.5 mL BAC water → concentration = 2000 mcg/mL (each 10 units on syringe = 200 mcg) - Add 1 mL BAC water → concentration = 5000 mcg/mL (each 10 units = 500 mcg) Step 3: Reconstitute. Wipe both vial tops with alcohol swabs. Draw the desired volume of BAC water into an insulin syringe. Insert the needle into the BPC-157 vial at an angle and inject slowly down the side of the vial — do not squirt directly onto the powder. Gently swirl (never shake) until fully dissolved. Step 4: Store. Refrigerate the reconstituted vial. Reconstituted BPC-157 is stable for approximately 28 days refrigerated. Label with the reconstitution date. Use the Staqk reconstitution calculator to determine your exact draw volume in syringe units for any vial size and BAC water combination.

Use the Staqk reconstitution calculator to find your exact draw volume in units for your vial size and target dose.

BPC-157 protocol design#

A well-structured BPC-157 protocol depends on your goal. Acute injury protocol (e.g., tendon, ligament, muscle tear): - Dose: 400–500 mcg, twice daily (morning + evening) - Duration: 4–8 weeks or until recovery is achieved - Injection: subcutaneous, ideally near the affected area Chronic or recurring injury: - Dose: 250–300 mcg, once daily - Duration: 8–12 weeks Gut health (IBS, IBD, leaky gut): - Oral capsules or sublingual preferred for GI targeting - Dose: 250–500 mcg, once daily before meals General recovery / off-season maintenance: - Dose: 250 mcg, once daily - Duration: 8–12 weeks, followed by a 4–8 week break Stack considerations: BPC-157 is commonly stacked with TB-500 (Thymosin Beta-4) for a synergistic tissue repair protocol. TB-500 adds systemic anti-inflammatory and actin modulation effects that complement BPC-157's more localised healing properties. This combination is sometimes called the Wolverine Stack.

BPC-157 vs TB-500: when to combine#

BPC-157 and TB-500 are the two most commonly combined peptides for injury repair and recovery. They have complementary mechanisms: BPC-157 primarily promotes local healing: angiogenesis near the injury site, tendon fibroblast activity, and GI mucosal repair. It works best near the injury. TB-500 works systemically: it sequesters actin (a structural protein), reduces inflammation broadly, and promotes cell migration and differentiation throughout the body. It is effective for systemic anti-inflammatory effects and accelerating repair in multiple sites simultaneously. Combined, they address both local repair (BPC-157) and systemic recovery conditions (TB-500). The BPC-157 + TB-500 stack is well-established in the research community and is the basis of what is called the Wolverine Stack — sometimes with Thymosin Alpha-1 added for immune system support. For isolated, single-site acute injuries: BPC-157 alone is often sufficient. For multi-site injuries, systemic inflammation, or aggressive training recovery: the BPC-157 + TB-500 combination is preferred.